Murali Janakiram, MD, MS

Assistant Professor of Medicine, Division of Hematology, Oncology and Transplantation

Murali Janakiram

Contact Info

Mailing Address:
420 Delaware Street SE
MMC 480
Minneapolis, MN 55455

Administrative Assistant Name
Pam Hansen

Administrative Email
hanse032@umn.edu

Assistant Professor of Medicine, Division of Hematology, Oncology and Transplantation


Hematologist
Oncologist


Madras Medical College, Chennai, Tamil Nadu

Internal Medicine Residency, Case Western Reserve University, Metro Health Medical Centre, Cleveland, Ohio

Hematology/Oncology Fellowship, Montefiore Medical Center, Albert Einstein College of Medicine, New York City, New York

Hematology Malignancies, Montefiore Medical Center, New York City, New York

MS (Clinical Research), Albert Einstein College of Medicine, New York City, New York

Summary

I am a board certified Hematologist/Oncologist and my clinical expertise is in aggressive lymphomas [T cell lymphoma, Adult T cell Leukemia Lymphoma, Viral associated lymphomas -HIV and HTLV, B cell lymphomas- DLCBL, Transformed lymphoma] and multiple myeloma. I focus on delivering the best clinical care for the patient which includes - new FDA approved drugs, access to clinical trial drugs, cellular therapy and Bone marrow transplant. Every individual patient is different and I help patients with lymphoma and myeloma choose the best option. My research interests are in T cell lymphoma, cellular therapy in lymphoma and myeloma and exploring immune checkpoints. I have done significant work in T cell lymphoma -Adult T cell Leukemia Lymphoma and elucidating the differences based on geographic location i.e patients presenting with the same disease in the US have a different genomic profile than Japanese patients with the same cancer. We also showed that the PD-1 blocking drug - Nivolumab, when used in this cancer can potentially worsen this disease which was published in New England Journal of Medicine. In cellular therapy, I have extensive experience in taking care and successfully treating patients with CAR T therapy in lymphoma. We have done educational programs on CART therapy for lymphoma and who should receive it. I believe that unanswered questions from patients should be translated to research in a scientific way to enhance basic and clinical understanding.

Expertise

  • Cellular Immunotherapy
  • T Cell Lymphoma
  • Relapsed Multiple Myeloma
  • Adult T Cell Leukemia Lymphoma
  • HIV Associated Lymphoma and Myeloma
  • Aggressive B Cell Lymphoma

Awards & Recognition

  • Clinical Scholars Scholarship, San Antonio Breast Cancer Symposium (2013)
  • Young Investigator Award, Eastern Cooperative Oncology (2013)
  • Outstanding Teaching Fellow of the Year Award, Montefiore Medical Centre (2012)

Professional Associations

  • American Society of Hematology; American Society of Oncology
  • ECOG Lymphoma/Myeloma Committee Member
  • AIDS Malignancy Consortium Member
  • Alberg Einstein Experimental Therapeutics Committee Member 

Research

Research Summary/Interests

  • Cellular Immunotherapy
  • Peripheral T Cell Lymphoma
  • Adult T cell Leukemia Lymphoma
  • Disparities in Multiple Myeloma
  • Immune checkpoints - PDL1, B7 H3, B7X, HHLA2

Research Funding Grants

  • Principal Investigator, Viral related haematological malignancies – HIV and HTLV supported by AIDS Malignancy Consortium

Publications

  • North American ATLL has a Distinct Mutational and Transcriptional Profile and responds to epigenetic therapies. Shah U, Chung EY, Kataoka K, Gordon-Mitchell S, Giricz O, Bhagat TD, Wei Y, Ishida E, Choudary G, Rice R, Wang Y, Ogawa S, Verma A, Ye BH, Janakiram M. Blood. 2018. doi: 10.1182/blood-2018-01-824607. PMID: 30104217.
  • Rapid Progression of Adult T-Cell Leukemia after PD-1 Inhibitor Therapy. Ratner L, Waldmann TA, Janakiram M, Brammer JE. N Engl J Med. 2018;378(20):1947-1948. PMID: 29768155.
  • Impact of Hepatitis B and C infection in cancer clinical trials recruitment. Janakiram M, Jasra S, Aboulafia DM. J Clin Oncol. 2018. PMID: 29381434.
  • Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma. Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, Younes A, Alekseev S, Illés Á, Picardi M, Lech-Maranda E, Oki Y, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Chen R, Ramchandren R, Zinzani PL, Cunningham D, Rosta A, Josephson NC, Song E, Sachs J, Liu R, Jolin HA, Huebner D, Radford J; ECHELON-1 Study Group. N Engl J Med. 2018;25;378(4):331-344. PMID: 29224502.
  • Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Horwitz S, O'Connor OA, Pro B, Illidge T, Fanale M, Advani R, Bartlett NL, Christensen JH, Morschhauser F, Domingo-Domenech E, Rossi G, Kim WS, Feldman T, Lennard A, Belada D, Illés Á, Tobinai K, Tsukasaki K, Yeh SP, Shustov A, Hüttmann A, Savage KJ, Yuen S, Iyer S, Zinzani PL, Hua Z, Little M, Rao S, Woolery J, Manley T, Trümper L; ECHELON-2 Study Group. Lancet. 2018. PMID: 30522922.
  • Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. Dimopoulos MA, Gay F, Schjesvold F, Beksac M, Hajek R, Weisel KC, Goldschmidt H, Maisnar V, Moreau P, Min CK, Pluta A, Chng WJ, Kaiser M, Zweegman S, Mateos MV, Spencer A, Iida S, Morgan G, Suryanarayan K, Teng Z, Skacel T, Palumbo A, Dash AB, Gupta N, Labotka R, Rajkumar SV; TOURMALINE-MM3 study group. Lancet. 2018. PMID: 30545780.
  • Expression, clinical significance, and receptor identification of the newest B7 family member HHLA2 protein. Janakiram M, Chinai J, Fineberg S, Fiser A, Montagna C, Medaverepu R, Castano E6, Jeon H1, Ohaegbulam KC, Zhao R, Zhao A, Almo S, Sparano JA, Zang X. Clin Cancer Res. 2015;15;21(10):2359-66, PMID: 25549724.
  • Immunotherapies targeting the PD-1 pathway. Chinai J, Janakiram M (co first author), Zang X. Trends Pharmacol Sci (Cell Press). 2015;36(9):587-95. PMID: 26162965.

Teaching

Academic Interests and Focus

Hematology

Clinical

Clinics

Blood and Marrow Transplant (BMT) Clinic;Clinics and Surgery Center;Masonic Cancer Center

Board Certifications

  • Hematology; Oncology
  • Internal Medicine

Clinical Interests

Cellular Immunotherapy; T Cell Lymphoma; Relapsed Multiple Myeloma; Adult T Cell Leukemia Lymphoma; HIV Associated Lymphoma and Myeloma; Aggressive B Cell Lymphoma

Hospital Privileges

Fairview Ridges Hospital; Fairview Lakes Medical Center; Fairview Northland Medical Center; Fairview Southdale Hospital; University of Minnesota Medical Center